ProQR Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
ProQR Therapeutics has a total shareholder equity of €25.0M and total debt of €4.5M, which brings its debt-to-equity ratio to 18.1%. Its total assets and total liabilities are €106.9M and €81.9M respectively.
Key information
18.1%
Debt to equity ratio
€4.51m
Debt
| Interest coverage ratio | n/a |
| Cash | €89.40m |
| Equity | €24.98m |
| Total liabilities | €81.87m |
| Total assets | €106.85m |
Recent financial health updates
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04Recent updates
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01Financial Position Analysis
Short Term Liabilities: PRQR's short term assets (€92.4M) exceed its short term liabilities (€39.6M).
Long Term Liabilities: PRQR's short term assets (€92.4M) exceed its long term liabilities (€42.2M).
Debt to Equity History and Analysis
Debt Level: PRQR has more cash than its total debt.
Reducing Debt: PRQR's debt to equity ratio has reduced from 18.1% to 18.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRQR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PRQR has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 13.4% each year.